Jean Drouin

Smart Health Network is neutral infrastructure for health transactions between providers, payers, and patients — built to help the industry modernize prior authorization ahead of the January 1, 2027 federal deadline. American healthcare still runs on faxes, phone calls, portals, and thousands of one-off connections. Clinicians lose hours to paperwork. Patients wait in the dark. Payers and providers rebuild the same integrations again and again. Smart Health Network changes the connection model: connect once, transact with all. The network routes eligibility, prior authorization, claims, remittance, attachments, and patient-visible audit through a neutral shared hub. Data stays at the source; the hub routes sealed envelopes and does not read or monetize patient data. Delaware launched first. The Delaware Department of Health and Social Services and the Delaware Health Care Commission announced a statewide initiative with DHIN and Smart Health Network to streamline insurance verification and prior authorization through shared infrastructure. Smart Health Network PBC is a mission-locked Delaware Public Benefit Corporation. Patient access, onboarding, conformance testing, and public-health reporting are permanently free. Published utility fees fund the network for payers and providers. Learn more: https://www.smarthealthnetwork.org

Cambia Health Solutions is a family of companies headquartered in Portland, Oregon, working to create a person-focused and economically sustainable health care system. Through our health plans, innovative technology and strategic investments, we are delivering consumer-centric solutions that: • help people achieve better health and well-being • make health care more available, affordable and accessible • are easily understood by everyone We put people at the heart of everything we do. Our company reaches more than 70 million Americans nationwide, including more than two million people in the Pacific Northwest who are enrolled in our regional health plans.

Clarify Health Solutions® is an enterprise analytics and value-based payments platform company that delivers end-to-end intelligence on every patient journey, empowering payers, providers, and life sciences companies to make better care decisions. Its unified platform, Atlas, maps over 300 million patient journeys, generates over 18 billion AI-powered predictions, and delivers insights with speed and precision via cloud software applications.

Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiaks discovery engine. Kodiaks lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development. KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. WORKING AT KODIAK We foster a culture of curiosity, creativity, compassion and courage. Our collective goal is to make a difference in the world. We do that as a team driven by the shared desire to tackle some of the world’s biggest challenges. If this sounds exciting, we want to hear from you! Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance. We are located in Palo Alto, in the heart of the world-class biotech hub of Silicon Valley, and within walking distance to California Avenue’s shops, restaurants and public transportation.

Smart Health Network is neutral infrastructure for health transactions between providers, payers, and patients — built to help the industry modernize prior authorization ahead of the January 1, 2027 federal deadline. American healthcare still runs on faxes, phone calls, portals, and thousands of one-off connections. Clinicians lose hours to paperwork. Patients wait in the dark. Payers and providers rebuild the same integrations again and again. Smart Health Network changes the connection model: connect once, transact with all. The network routes eligibility, prior authorization, claims, remittance, attachments, and patient-visible audit through a neutral shared hub. Data stays at the source; the hub routes sealed envelopes and does not read or monetize patient data. Delaware launched first. The Delaware Department of Health and Social Services and the Delaware Health Care Commission announced a statewide initiative with DHIN and Smart Health Network to streamline insurance verification and prior authorization through shared infrastructure. Smart Health Network PBC is a mission-locked Delaware Public Benefit Corporation. Patient access, onboarding, conformance testing, and public-health reporting are permanently free. Published utility fees fund the network for payers and providers. Learn more: https://www.smarthealthnetwork.org

Cambia Health Solutions is a family of companies headquartered in Portland, Oregon, working to create a person-focused and economically sustainable health care system. Through our health plans, innovative technology and strategic investments, we are delivering consumer-centric solutions that: • help people achieve better health and well-being • make health care more available, affordable and accessible • are easily understood by everyone We put people at the heart of everything we do. Our company reaches more than 70 million Americans nationwide, including more than two million people in the Pacific Northwest who are enrolled in our regional health plans.

Since 1922, the Columbia Universitys Mailman School of Public Health has been at the forefront of public health research, education, and community collaboration. Addressing everything from chronic disease to HIV/AIDS to healthcare policy, the School tackles today’s pressing public health issues, translating research results into action.

Clarify Health Solutions® is an enterprise analytics and value-based payments platform company that delivers end-to-end intelligence on every patient journey, empowering payers, providers, and life sciences companies to make better care decisions. Its unified platform, Atlas, maps over 300 million patient journeys, generates over 18 billion AI-powered predictions, and delivers insights with speed and precision via cloud software applications.

Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiaks discovery engine. Kodiaks lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development. KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. WORKING AT KODIAK We foster a culture of curiosity, creativity, compassion and courage. Our collective goal is to make a difference in the world. We do that as a team driven by the shared desire to tackle some of the world’s biggest challenges. If this sounds exciting, we want to hear from you! Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance. We are located in Palo Alto, in the heart of the world-class biotech hub of Silicon Valley, and within walking distance to California Avenue’s shops, restaurants and public transportation.